Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07647081

The Impacts of Ashwagandha Supplementation on Diurnal Cortisol and Stress Among Women

The purpose of this project is to better understand the role of ashwagandha on the stress response and wellbeing among healthy, stressed women.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Stress

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

About this study

This study will add knowledge about how ashwagandha can impact diurnal cortisol values (at waking, 30 minutes-post waking, and bedtime). This study will also assess the impact of ashwagandha consumption on inflammatory biomarkers and self-reported perceived stress, anxiety, and well-being among females.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female, ages 18-45
  • No hormonal birth control
  • Identify as having a regular sleep schedule (eg. sleep by 1am and wake by 9am)
  • Identify as having a regular menstrual period between 27-32 days apart on average
  • PSS score of 14 (moderate stress) or greater
  • No expected changes in stress levels over the next 3 months and agree to not initiate any new stress-reduction behaviors before study start or during the study

Exclusion criteria

  • Diagnosed major depressive disorder or generalized anxiety disorder in the last 3 months, any liver, kidney, or thyroid disorder/dysfunction/injury, or diabetes
  • Using any medication related to cortisol or HPA function such as corticosteroids, antidepressants, anti-psychotics, CNS-depressants (benzodiazepines, non-benzodiazepine sedatives, barbiturates, anti-convulsants, anesthetics), thyroid medications, diabetic medications, or immunosuppressants
  • Taken any form of ashwagandha within the last 3 months
  • Daily use of alcohol, nicotine, or other substances
  • Who are pregnant, planning to become pregnant, breastfeeding, or have had a hysterectomy
  • Abnormal liver function test value(s) at screening

Treatment and study plan

Placebo

Other

Brown Rice Powder

KSM-66 Ashwagandha

Dietary Supplement

600mg daily KSM-66 Ashwagandha

Other names: withania somnifera, KSM66, KSM-66

Primary outcomes

  1. Diurnal Salivary Cortisol Change from Baseline to ~4 weeks and ~8 weeks

    Time frame: Baseline, ~4 weeks,. ~8weeks

    Saliva swabs from waking, 30 minutes post-waking, and bedtime will be analyzed to compare cortisol levels and diurnal changes across timepoints from baseline to ~4 weeks and ~8 weeks (as corresponding to participants menstrual cycle).

  2. HRV Change from Baseline to ~4 weeks and ~8 weeks

    Time frame: Baseline, ~4 weeks,. ~8weeks

    Wearable biometric device data will be used to compare heart rate variability (HRV) from baseline to ~4 weeks and ~ 8 weeks (as corresponding to participants menstrual cycle).

Secondary outcomes

  1. Perceived Stress Scale (PSS)

    Time frame: Baseline, ~4 weeks,. ~8weeks

    Perceived Stress Scale (PSS) data will be used to compare changes from baseline to ~4 weeks and ~ 8 weeks (as corresponding to participants menstrual cycle).

    Individual scores can range from 0 to 40 with higher scores correlating with higher levels of perceived stress.

    0-13: Low Stress 14-26: Moderate Stress 27-40: High Perceived Stress

  2. Hamilton Anxiety Rating Scale (HAM-A)

    Time frame: Baseline, ~4 weeks,. ~8weeks

    Hamilton Anxiety Rating Scale (HAM-A) data will be used to compare changes from baseline to ~4 weeks and ~ 8 weeks (as corresponding to participants menstrual cycle).

    Each item is scored on a scale of 0 (not present) to 4 (severe). Total scores range of 0-56.

    0-17: Mild severity 18-24: Mild to moderate severity 25-30: Moderate to severe

  3. Depression Anxiety Stress Scale-21 (DASS21)

    Time frame: Baseline, ~4 weeks,. ~8weeks

    Depression Anxiety Stress Scale-21 (DASS21) data will be used to compare subset scales for depression, anxiety and stress changes from baseline to ~4 weeks and ~ 8 weeks (as corresponding to participants menstrual cycle).

    DASS21 is a set of three scales designed to measure the emotional states of depression, anxiety and stress. Scores can range from normal to extremely severe for each domain.

    Each item is scored on a scale of 0 (Did not apply to me at all) to 3 (Applied to me very much or most of the time).

  4. World Health Organization-Five Well-Being Index (WHO-5)

    Time frame: Baseline, ~4 weeks,. ~8weeks

    World Health Organization-Five Well-Being Index (WHO-5) data will be used to compare mental wellbeing changes from baseline to ~4 weeks and ~ 8 weeks (as corresponding to participants menstrual cycle).

    Each item is scored on a scale of 0 (at no time) to 5 (all of the time). Total scores range from 0 to 25. With 0 representing worst possible and 25 representing best possible quality of life.

  5. Sleep Quality Change from Baseline to ~4 weeks and ~8 weeks

    Time frame: Baseline, ~4 weeks,. ~8weeks

    Wearable biometric device data will be used to compare sleep quality, latency, and duration from baseline to ~4 weeks and ~ 8 weeks (as corresponding to participants menstrual cycle).

Study contacts

Contact information is provided by the study sponsor or research team.

Research Scientist

CONTACT

[email protected]

918-517-6151

Sponsors and collaborators

Lead sponsor

Oklahoma State University Center for Health Sciences

Other

Registry information

Official study title

Female Adversity and Biology: Stress Reduction

Acronym: FAB:SR

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jun 15, 2026
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.